Polylactic acid and lanolin based nanofibrous structures for wound management application

Polylactic acid (PLA) polymer and wool oil (lanolin) have been used to develop nanostructures for wound dressing management. Lanolin has been extracted from raw wool surfaces and used as a by-product in wide range of pharmaceutical areas. Different solutions with varying concentration of the PLA/lanolin and sodium alginate/lanolin solutions have been prepared and then nanostructures are developed using electrospinning method. The developed structures are aimed to use as smart wound dressings. During the production stage, the parameters of the electrospinning process have been changed to develop the optimum structures. The effect of solution concentrations on the applied voltage and the distance between the pipette tip and the collector is highlighted. The spinnability of lanolin is the main objectives of this study and the PLA/lanolin nanostructures are designed and manufactured successfully. The essential test methods have been performed to measure the usability of the produced materials as wound dressings. These are liquid absorption capacity, horizontal/vertical wicking, SEM, degradation, pH, antibacterial assay, and tensile properties. From the tested parameters, it is obviously found that the use of PLA/lanolin as wound dressing is suitable according to initial in vitro test results

GROUP 12 ELEMENTS AND THEIR SMALL CLUSTERS: ELECTRIC DIPOLE POLARIZABILITY OF Zn, Cd AND H-g, Zn-2 DIMER AND HIGHER Zn-n MICROCLUSTERS AND NEUTRAL, CATIONIC AND ANIONIC ZINC OXIDE MOLECULES (ZnO, ZnO+ AND ZnO-)

This review is in general about group 12 elements and their small microclusters. In this part, after presenting an extensive literature survey of the electric dipole polarizability studies of the Zn, Cd and Hg atoms, we specifically target zinc-containing small clusters, beginning with the Zn-2 dimer, the Zn-3 trimer, higher Zn-n clusters and the neutral, cationic and anionic zinc oxide clusters: ZnO, ZnO+ and ZnO-. We tabulated experimental and theoretical results for the spectroscopic constants (dissociation energy D-e or D-0, bond length r(e), fundamental frequency w(e), anharmonicity constant w(e)x(e) and dipole moment mu(e)) of the diatomic clusters and the first and second ionization potentials IP1 and IP2 and electron affinity EA of the species reviewed

THE ASSOCIATION BETWEEN HLA CLASS I AND II ALLELES AND THE OCCURRENCE OF INHIBITORS IN TURKISH PATIENTS WITH HEMOPHILIA A: A PILOT STUDY

WOS: 000464517600201

THE ASSOCIATION BETWEEN HLA CLASS I AND II ALLELES AND THE OCCURRENCE OF INHIBITORS IN TURKISH PATIENTS WITH HEMOPHILIA A: A PILOT STUDY

WOS: 00046451760020

Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate

Purpose To evaluate the potential benefit of curative radiotherapy (RT) to the primary tumor in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone. Materials and methods The clinical parameters of 106 mCRPC patients treated with abiraterone were retrospectively evaluated. Patients were either oligometastatic (<= 5 metastases) at diagnosis or became oligometastatic after the systemic treatment was analyzed. Local RT to the primary tumor and pelvic lymphatics was delivered in 44 patients (41%), and 62 patients (59%) did not have RT to the primary tumor. After propensity match analysis, a total of 92 patients were analyzed. Resultsn Median follow-up time was 14.2 months (range: 2.3-54.9 months). Median overall survival (OS) was higher in patients treated with local RT to the primary tumor than in those treated without local RT with borderline significance (24.1 vs. 21.4 months; p=0.08). Local RT to the prostate and pelvic lymphatics significantly diminished the local recurrence rate (16 patients, 31% vs. 2 patients, 5%; p=0.003). In multivariate analysis, the prostate specific antigen (PSA) response >= 50% of the baseline obtained 3 weeks after abiraterone therapy was the only significant prognostic factor for better OS and progression-free survival (PFS). Patients treated with primary RT to the prostate had significantly less progression under abiraterone and a longer abiraterone period than those treated without local prostate RT. Conclusions Local prostate RT significantly improved OS and local control in mCRPC patients treated with abiraterone. The patients treated with primary RT had significantly less progression under abiraterone and a longer abiraterone period than those treated without local prostate RT

Infantile-onset thiamine responsive megaloblastic anemia syndrome with SLC19A2 mutation: a case report

Background. Thiamine-responsive megaloblastic anemia syndrome (TRMA), also known as Rogers syndrome, is characterized by megaloblastic anemia, sensorineural hearing loss, and diabetes mellitus. Disturbances of the thiamine transport into the cells results from homozygous or compound heterozygous mutations in the SLC19A2 gene

Turkish National Severe Congenital Neutropenia Registry

58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) -- DEC 03-06, 2016 -- San Diego, CAWOS: 000394452701110Amer Soc HematolTUBITAKTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)Yilmaz Karapinar: TUBITAK: Research Funding

Factor 8 Gene Mutation Spectrum of 270 Patients with Hemophilia A: Identification of 36 Novel Mutations

Objective: Hemophilia A (HA) is the most severe X-linked inherited bleeding disorder caused by hemizygous mutations in the factor 8 (F8) gene. The aim of this study is to determine the mutation spectrum of the F8 gene in a large HA cohort from Turkey, and then to establish a phenotype-genotype correlation

Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey

Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children